Medical diagnostics company STAT - Diagnostica has closed a Series C financing round totaling 25 million Euros/ 28.5 million USD . The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system . Led by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Venture Fund ; Caixa Capital Risc ; and Axis. “
STAT - Diagnostica’s DiagCORE system can become the best - in - class platform for decentralized molecular testing, the most attr active growth area in molecular diagnostics today,” said Arthur Franken , partner , Gilde Healthcare. “ The company’s exceptional team has taken the product from idea to commercial implementation in just a few years, a tremendous achievement that stands to bring significant benefit to practitioners and patients.”
“ We are very pleased to have strengthened our existing investor base with Gilde Healthcare , ” said Jordi Carrera, CEO and co - founder of STAT - Diagnostica. “ This transaction paves the way for us to become the leader in the decentralized syndromic - approach diagnostics space, the fastest growing segment of in - vitro diagnostics . ” DiagCORE is a fully integrated molecular and immunoassay diagnostics system that delivers lab - like performance in just one step, providing unrivaled usability for true walk - away diagnostics. DiagCORE performs all sample prep steps on board for a wide range of sample types (e.g., whole blood, swabs, BAL, stool, sputum) while offering up to 48 - multiplex capabilities via real - time PCR. Time to results can be as low as 30 and up to 80 minutes, depending on the assay type .
DiagCORE’s rapid performance is expected to improve clinical decision making and deliver better patient management and cost savings to the healthcare system.
STAT - Diagnostica plans to target a range of decentralized testing environments with DiagCORE , inc l uding critical c are and emergency medicine units within hospitals. The system will also have CLIA - waivable features that will allow it to be used in clinics and physician offices.
About STAT - Diagnostica
Founded in 2010 in Barcelona, STAT - Diagnostica is focused on the dev elopment of Near Patient Testing solutions where fast and accurate diagnostic results are needed. Its DiagCORE in vitro diagnostic system is a versatile, easy - to - use platform that consolidates molecular and immunoassay techniques in a single device
Source of Press Releas in English: Ysios Capital